Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The event, scheduled for September 16 at 8:30 a.m. EDT, will be webcast live, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website. For full details, see the press release.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company founded in 2019. The company is committed to helping minds heal by developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. These NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health. The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. Helus Pharma also maintains an extensive research portfolio of investigational NSAs.
The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information and company updates, visit www.helus.com or follow Helus Pharma on X, LinkedIn, YouTube, and Instagram. Helus Pharma(TM) is a trademark of Cybin Corp.
The presentation at the Morgan Stanley conference comes at a critical time for Helus Pharma as it advances its pipeline. The Breakthrough Therapy Designation for HLP003 underscores the potential of its NSA platform to address major depressive disorder, a condition that affects millions worldwide. With Phase 3 trials underway, the company is positioning itself as a leader in the emerging field of serotonergic agonists. For investors and industry observers, the fireside chat may provide insights into upcoming milestones and the company's strategic direction.
Mental health disorders such as depression and anxiety have seen rising prevalence, and existing treatments often fall short for many patients. Helus Pharma's focus on novel mechanisms could offer new hope. The outcomes of its clinical programs will be closely watched, as successful development could significantly impact treatment paradigms and improve patient outcomes. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP.
